Advances in the Treatment of Renal Cell Carcinoma
This Special Issue of Cancers focuses on new advances in the treatment of renal cell carcinoma, both surgical and pharmacological (and combinations of these), and novel approaches to tackle treatment resistance and improve our understanding of this phenomenon.
Saved in:
HerausgeberIn: | |
---|---|
Sonstige: | |
Year of Publication: | 2022 |
Language: | English |
Physical Description: | 1 electronic resource (221 p.) |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
id |
993545720104498 |
---|---|
ctrlnum |
(CKB)5400000000045247 (oapen)https://directory.doabooks.org/handle/20.500.12854/79585 (EXLCZ)995400000000045247 |
collection |
bib_alma |
record_format |
marc |
spelling |
Reynolds, Paul edt Advances in the Treatment of Renal Cell Carcinoma Basel MDPI - Multidisciplinary Digital Publishing Institute 2022 1 electronic resource (221 p.) text txt rdacontent computer c rdamedia online resource cr rdacarrier Open access Unrestricted online access star This Special Issue of Cancers focuses on new advances in the treatment of renal cell carcinoma, both surgical and pharmacological (and combinations of these), and novel approaches to tackle treatment resistance and improve our understanding of this phenomenon. English Medicine bicssc renal cell carcinoma autophagy hydroxychloroquine chloroquine ROC-325 cysteine cathepsins cysteine cathepsin inhibitors lysosome renal cancer metastatic renal cell carcinoma immune-based combination therapies network meta-analysis PD-L1 predictive biomarker treatment TKIs mRCC biomarkers soluble factors immunotherapy renal cell carcinoma (RCC) sunitib resistance artesunate (ART) Traditional Chinese Medicine (TCM) growth inhibition ferroptosis reactive oxygen species (ROS) clear cell renal cell carcinoma ccRCC RCC kidney cancer evolution evolutionary trajectory metastatic second line therapy renal cell cancer immune checkpoint inhibitors tyrosine kinase inhibitors individualization genomic signature transcriptomic analysis 3-0365-2935-7 3-0365-2934-9 Stewart, Grant D edt Reynolds, Paul oth Stewart, Grant D oth |
language |
English |
format |
eBook |
author2 |
Stewart, Grant D Reynolds, Paul Stewart, Grant D |
author_facet |
Stewart, Grant D Reynolds, Paul Stewart, Grant D |
author2_variant |
p r pr g d s gd gds |
author2_role |
HerausgeberIn Sonstige Sonstige |
title |
Advances in the Treatment of Renal Cell Carcinoma |
spellingShingle |
Advances in the Treatment of Renal Cell Carcinoma |
title_full |
Advances in the Treatment of Renal Cell Carcinoma |
title_fullStr |
Advances in the Treatment of Renal Cell Carcinoma |
title_full_unstemmed |
Advances in the Treatment of Renal Cell Carcinoma |
title_auth |
Advances in the Treatment of Renal Cell Carcinoma |
title_new |
Advances in the Treatment of Renal Cell Carcinoma |
title_sort |
advances in the treatment of renal cell carcinoma |
publisher |
MDPI - Multidisciplinary Digital Publishing Institute |
publishDate |
2022 |
physical |
1 electronic resource (221 p.) |
isbn |
3-0365-2935-7 3-0365-2934-9 |
illustrated |
Not Illustrated |
work_keys_str_mv |
AT reynoldspaul advancesinthetreatmentofrenalcellcarcinoma AT stewartgrantd advancesinthetreatmentofrenalcellcarcinoma |
status_str |
n |
ids_txt_mv |
(CKB)5400000000045247 (oapen)https://directory.doabooks.org/handle/20.500.12854/79585 (EXLCZ)995400000000045247 |
carrierType_str_mv |
cr |
is_hierarchy_title |
Advances in the Treatment of Renal Cell Carcinoma |
author2_original_writing_str_mv |
noLinkedField noLinkedField noLinkedField |
_version_ |
1796648786722816000 |
fullrecord |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>02684nam-a2200829z--4500</leader><controlfield tag="001">993545720104498</controlfield><controlfield tag="005">20231214133418.0</controlfield><controlfield tag="006">m o d </controlfield><controlfield tag="007">cr|mn|---annan</controlfield><controlfield tag="008">202203s2022 xx |||||o ||| 0|eng d</controlfield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(CKB)5400000000045247</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(oapen)https://directory.doabooks.org/handle/20.500.12854/79585</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(EXLCZ)995400000000045247</subfield></datafield><datafield tag="041" ind1="0" ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Reynolds, Paul</subfield><subfield code="4">edt</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Advances in the Treatment of Renal Cell Carcinoma</subfield></datafield><datafield tag="260" ind1=" " ind2=" "><subfield code="a">Basel</subfield><subfield code="b">MDPI - Multidisciplinary Digital Publishing Institute</subfield><subfield code="c">2022</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">1 electronic resource (221 p.)</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">computer</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">online resource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="506" ind1=" " ind2=" "><subfield code="a">Open access</subfield><subfield code="f">Unrestricted online access</subfield><subfield code="2">star</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">This Special Issue of Cancers focuses on new advances in the treatment of renal cell carcinoma, both surgical and pharmacological (and combinations of these), and novel approaches to tackle treatment resistance and improve our understanding of this phenomenon.</subfield></datafield><datafield tag="546" ind1=" " ind2=" "><subfield code="a">English</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Medicine</subfield><subfield code="2">bicssc</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">renal cell carcinoma</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">autophagy</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">hydroxychloroquine</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">chloroquine</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">ROC-325</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">cysteine cathepsins</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">cysteine cathepsin inhibitors</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">lysosome</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">renal cancer</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">metastatic renal cell carcinoma</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">immune-based combination therapies</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">network meta-analysis</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">PD-L1</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">predictive</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">biomarker</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">treatment</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">TKIs</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">mRCC</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">biomarkers</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">soluble factors</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">immunotherapy</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">renal cell carcinoma (RCC)</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">sunitib resistance</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">artesunate (ART)</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">Traditional Chinese Medicine (TCM)</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">growth inhibition</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">ferroptosis</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">reactive oxygen species (ROS)</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">clear cell renal cell carcinoma</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">ccRCC</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">RCC</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">kidney cancer</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">evolution</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">evolutionary trajectory</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">metastatic</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">second line therapy</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">renal cell cancer</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">immune checkpoint inhibitors</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">tyrosine kinase inhibitors</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">individualization</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">genomic signature</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">transcriptomic analysis</subfield></datafield><datafield tag="776" ind1=" " ind2=" "><subfield code="z">3-0365-2935-7</subfield></datafield><datafield tag="776" ind1=" " ind2=" "><subfield code="z">3-0365-2934-9</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Stewart, Grant D</subfield><subfield code="4">edt</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Reynolds, Paul</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Stewart, Grant D</subfield><subfield code="4">oth</subfield></datafield><datafield tag="906" ind1=" " ind2=" "><subfield code="a">BOOK</subfield></datafield><datafield tag="ADM" ind1=" " ind2=" "><subfield code="b">2023-12-15 05:53:22 Europe/Vienna</subfield><subfield code="f">system</subfield><subfield code="c">marc21</subfield><subfield code="a">2022-04-04 09:22:53 Europe/Vienna</subfield><subfield code="g">false</subfield></datafield><datafield tag="AVE" ind1=" " ind2=" "><subfield code="i">DOAB Directory of Open Access Books</subfield><subfield code="P">DOAB Directory of Open Access Books</subfield><subfield code="x">https://eu02.alma.exlibrisgroup.com/view/uresolver/43ACC_OEAW/openurl?u.ignore_date_coverage=true&portfolio_pid=5338048590004498&Force_direct=true</subfield><subfield code="Z">5338048590004498</subfield><subfield code="b">Available</subfield><subfield code="8">5338048590004498</subfield></datafield></record></collection> |